Nanjing Edcheng Ningxin Pharmaceutical Research and Development Co., Ltd.

Primary objective To evaluate the preliminary efficacy of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment. Secondary objective To evaluate the safety of AL2846 capsules in patients with iodine-refractory differentiated thyroid cancer who have failed previous TKI treatment.

Primary objective: To evaluate the safety and tolerability of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors, observe the occurrence of DLT, and determine the MTD and RP2D. Secondary objective: To preliminarily obtain the pharmacokinetic parameters of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors (only the first part). Preliminary evaluation of the effectiveness of AL8326 tablets combined with Toripalimab in the treatment of advanced solid tumors

【Phase I (dose introduction)】 Evaluate the safety of AL2846 capsules in Chinese patients with neurofibromatosis type 1 (NF1)-related (neurofibromas and peripheral malignant nerve sheath tumors) and the recommended dose for Phase II clinical trials. 【Phase II (cohort expansion)】 Preliminary evaluation of the efficacy and safety of AL2846 capsules in Chinese patients with neurofibromatosis type 1 (NF1)-related (neurofibromas and peripheral malignant nerve sheath tumors), and exploration of relevant therapeutic markers.